EGFR and non-small cell lung carcinoma: DARPP-32 knockdown sensitizes gefitinib-resistant NSCLC tumors to EGFR inhibition in vivo, whereas no such effect was observed in mice challenged with control LacZ shRNA-transduced HCC827GR cells (Fig. 7b and Supplementary Fig. 13a).